Consistency of Response With Rimegepant in Acute Treatment of Migraine

Prior treatment

• Current use of rimegepant as a preventive migraine medication.
• Current prescription of any of the following medications:
  • Strong inhibitors of CYP3A4
  • Strong or moderate inducers of CYP3A4

Other illness

• Current diagnosis of any of the following conditions:
  • new daily persistent headache
  • chronic daily headache
  • cluster headache
  • post-traumatic headache
  • hemicrania continua
  • major depression
  • pain syndromes other than migraine (e.g. fibromyalgia)
  • psychiatric conditions (e.g., schizophrenia)
  • dementia
  • significant neurological disorders other than migraine.

Other

• Patients participating in a migraine-related clinical trial.

• UK resident.
• At least 18 years of age.
• Migraine diagnosis confirmed by healthcare professional.
• Current prescription of rimegepant for acute treatment of migraine.
• Experienced at least 4 migraine attacks per month prior to study enrolment.
• In the case of participants receiving preventive migraine treatment:
  • For oral preventives, the treatment must be "stable" i.e., final dosing regimen has been found.
  • For migraine preventives administered monthly, the participant must have had their most recent treatment within the 3 weeks prior to study enrolment.
  • For migraine preventives administered quarterly, the participant must have had their most recent treatment within the 2 months prior to study enrolment.
  • If the last treatment is not within the stipulated period, participants will be asked to provide the date of the next scheduled treatment, after which the participant may be invited back to enrol into the study.
• Evidence of a personally signed (or acknowledged if obtained electronically or online) and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.